Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2003 1
2005 1
2007 3
2008 3
2009 1
2010 5
2011 5
2012 5
2013 9
2014 9
2015 11
2016 18
2017 20
2018 13
2019 12
2020 14
2021 13
2022 9
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25851308

135 results

Results by year

Filters applied: . Clear all
Page 1
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.
Martín M, González-Rivera M, Morales S, de la Haba-Rodriguez J, González-Cortijo L, Manso L, Albanell J, González-Martín A, González S, Arcusa A, de la Cruz-Merino L, Rojo F, Vidal M, Galván P, Aguirre E, Morales C, Ferree S, Pompilio K, Casas M, Caballero R, Goicoechea U, Carrasco E, Michalopoulos S, Hornberger J, Prat A. Martín M, et al. Curr Med Res Opin. 2015 Jun;31(6):1129-37. doi: 10.1185/03007995.2015.1037730. Epub 2015 Apr 23. Curr Med Res Opin. 2015. PMID: 25851308
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
Hequet D, Callens C, Gentien D, Albaud B, Mouret-Reynier MA, Dubot C, Cottu P, Huchon C, Zilberman S, Berseneff H, Foa C, Salmon R, Roulot A, Lerebours F, Salomon A, Ghali N, Morel P, Li Q, Cayre A, Guinebretière JM, Hornberger J, Penault-Llorca F, Rouzier R. Hequet D, et al. PLoS One. 2017 Oct 18;12(10):e0185753. doi: 10.1371/journal.pone.0185753. eCollection 2017. PLoS One. 2017. PMID: 29045452 Free PMC article.
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein R, Sotlar K, Gluz O, Otremba B, von Schumann R, Witzel I, Schindlbeck C, Janni W, Schem C, Bauerfeind I, Hasmueller S, Tesch H, Paulenz A, Ghali N, Orujov E, Kates RE, Cowens W, Hornberger J, Pelz E, Harbeck N. Wuerstlein R, et al. Curr Med Res Opin. 2016 Jul;32(7):1217-24. doi: 10.1185/03007995.2016.1166102. Epub 2016 Mar 30. Curr Med Res Opin. 2016. PMID: 26971372
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
Gligorov J, Pivot XB, Jacot W, Naman HL, Spaeth D, Misset JL, Largillier R, Sautiere JL, de Roquancourt A, Pomel C, Rouanet P, Rouzier R, Penault-Llorca FM; Francilian Breast Intergroup. Gligorov J, et al. Oncologist. 2015 Aug;20(8):873-9. doi: 10.1634/theoncologist.2014-0467. Epub 2015 Jun 25. Oncologist. 2015. PMID: 26112003 Free PMC article.
The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
Leung RC, Yau TC, Chan MC, Chan SW, Chan TW, Tsang YY, Wong TT, Chao C, Yoshizawa C, Soong IS, Kwan WH, Kwok CC, Suen JS, Ngan RK, Cheung PS. Leung RC, et al. Clin Breast Cancer. 2016 Oct;16(5):372-378. doi: 10.1016/j.clbc.2016.03.002. Epub 2016 Mar 17. Clin Breast Cancer. 2016. PMID: 27105769 Free article.
Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
Albanell J, Svedman C, Gligorov J, Holt SD, Bertelli G, Blohmer JU, Rouzier R, Lluch A, Eiermann W. Albanell J, et al. Eur J Cancer. 2016 Oct;66:104-13. doi: 10.1016/j.ejca.2016.06.027. Epub 2016 Aug 18. Eur J Cancer. 2016. PMID: 27544930 Free article.
Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Sanft T, et al. Breast Cancer Res Treat. 2015 Dec;154(3):533-41. doi: 10.1007/s10549-015-3631-9. Epub 2015 Nov 14. Breast Cancer Res Treat. 2015. PMID: 26578401 Free PMC article.
[Effect of 21-gene recurrence score on chemotherapy decisions for patients with estrogen receptor-positive, epidermal growth factor receptor 2-negative and lymph node-negative early stage-breast cancer].
Mao Y, Chen XS, Liang Y, Wu JY, Huang O, Zong Y, Fang Q, He JR, Zhu L, Chen WG, Li YF, Lin L, Fei XC, Shen KW. Mao Y, et al. Zhonghua Zhong Liu Za Zhi. 2017 Jul 23;39(7):502-508. doi: 10.3760/cma.j.issn.0253-3766.2017.07.005. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28728295 Chinese.
135 results